Skip to main content

Table 4 Adverse events during chemotherapy (18 patients, 146 cycles)

From: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

 

Patients with biliary stent (n = 9)

Patients without biliary stent (n = 9)

All patients (n = 18)

Adverse event

Grade 1/2

Grade 3/4

Grade 1/2

Grade 3/4

Grade 1/2

Grade 3/4

 

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Hematological

Neutropenia

3 (33 %)

3 (33 %)

3 (33 %)

1 (11 %)

6 (33 %)

4 (22 %)

Neutropenic fever

0

2 (22 %)

0

1 (11 %)

0

3 (17 %)

Anemia

6 (67 %)

2 (22 %)

7 (78 %)

0

13 (72 %)

2 (11 %)

Thrombocytopenia

3 (33 %)

3 (33 %)

5 (56 %)

0

8 (44 %)

3 (17 %)

Non-hematological

Fatigue

6 (67 %)

1 (11 %)

8 (89 %)

1 (11 %)

14 (78 %)

2 (11 %)

Anorexia

3 (33 %)

0

1 (11 %)

0

4 (22 %)

0

Mucositis

1 (11 %)

0

1 (11 %)

0

2 (11 %)

0

Nausea

5 (56 %)

0

4 (11 %)

0

9 (50 %)

0

Vomiting

0

0

2 (22 %)

0

2 (11 %)

0

Diarrhea

3 (33 %)

1 (11 %)

3 (33 %)

1 (11 %)

6 (33 %)

2 (11 %)

Peripheral neuropathy

1 (11 %)

0

5 (56 %)

0

6 (33 %)

0

Alopecia

6 (67 %)

0

6 (67 %)

0

12 (67 %)

0